Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence

Conclusions
These extensions will allow for better personalised risks for BARD1, RAD51C, RAD51D and PALB2 pathogenic variant carriers and more informed choices on screening, prevention, risk factor modification or other risk-reducing options.

Source: Journal of Medical Genetics - November 22, 2022 Category: Genetics & Stem Cells Authors: Lee, A., Mavaddat, N., Cunningham, A., Carver, T., Ficorella, L., Archer, S., Walter, F. M., Tischkowitz, M., Roberts, J., Usher-Smith, J., Simard, J., Schmidt, M. K., Devilee, P., Zadnik, V., Jürgens, H., Mouret-Fourme, E., De Pauw, A., Rookus, M Tags: Open access Cancer genetics Source Type: research